Back To: Home





December 3-5, 2014
World Stem Cell Summit - SAn Antonio, TX

December 6-10, 2014

More Events
Name:
Company:
Email:
 
 
 



November 2014
After decades of questionable results, are disease models turning a corner?...
by Randall C Willis

November 2014
Johnson & Johnson deals out $1.75B for respiratory disease company Alios...
by Kelsey Kaustinen

November 2014
Endo to acquire Auxilium Pharmaceuticals in a cash-and-stock transaction for approximately $2.6 billion...
by Jeffrey Bouley

November 2014
Pharmaceutical companies to share data for drug design via new UC San Diego-led resource...
by Lloyd Dunlap

October 2014
Merck KGaA acquiring Sigma-Aldrich to enhance position in increasingly attractive life-sciences market...
by Jeffrey Bouley

October 2014
Mayo Clinic and IBM to apply Watson to clinical trial enrollment...
by Kelsey Kaustinen



SHOW PREVIEW:
American Society for Cell Biology (ASCB)
Dec. 6-10, 2014
As you will see in our conference preview article, the 54th  Annual Meeting of the ASCB at the Pennsylvania Convention Center in Philadelphia will cover a wide array of topics as part of its overall program and special sessions, including engineering, physics, computational modeling and quantitative methods. [read more]

From ISSCR 2014, here are  reports from the field by DDNews Features Editor Randall C Willis ...
 
"Taking stem cells from bench to business"
"Building a better model"
"Shifting stem cell regulatory landscape"
"Patients' growing impatience for cell therapies"

 Our 2015 Media Kit is now available
 
 

 
Your gateway to the latest oncology news, trends and resources


November 2014
At the crossroads of understanding cell physiology, disease pathology and etiology is cell metabolism, which is widely known to be a common feature of these costly, debilitating and lethal diseases. In part because of this, The next decade will witness the release of a new class of drugs, known as “metabolo-therapeutics,” which will target metabolic pathways and the individual metabolites that are required for the maintenance of normal health. .. [ more ]
by D.A. Ferrick & V. Darley-Usmar

November 2014
Is it time for Health Canada to give up on regulation of drugs and medical devices, following the lead of the U.S. FDA on that front and focusing on other public health duties for which it is better equipped?.. [ more ]
by Randall C Willis

November 2014
Conducting clinical trials in "developing nations" and other places that aren't part of the so-called First World has been great for some pharmas and biotechs in terms of cutting costs and increasing recruitment, but the cost benefits won't last forever.. [ more ]
by Jeffrey Bouley












CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2014 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.